Results 1 to 10 of about 46 (43)
Eating disorders in young patients with neurofibromatosis type 1
Aim We describe the association of neurofibromatosis type 1 (NF1) and feeding and eating disorders (FED) in five patients admitted to our third level centre for both FED and NF1. Methods Case series of five adolescent females with NF1 treated for FED. Results We collected data from five patients with NF1 aged between 14 and 22 years, all females.
Francesca Chiavarino +5 more
wiley +1 more source
A multiphase biomaterial ink combining type‐I‐collagen with nano‐sized mesoporous bioactive glasses and nanohydroxyapatite was successfully designed to mimic the natural composition of bone. Based on rheological data and computational‐fluid‐dynamic models, the printing set‐up was optimized to obtain scaffolds characterized by high printing fidelity and
Giorgia Montalbano +2 more
wiley +1 more source
Cuproptosis Inducers in Cancer Therapy: State of the Art and Challenges
Cuproptosis is emerging as a distinct copper‐dependent cell death pathway, highlighting copper as a potential metabolic vulnerability in cancer. This review examines how coordination chemistry, redox regulation, and nanomaterial design shape Cu reactivity and therapeutic outcomes.
Chiara Ragusa, Valentina Oliveri
wiley +1 more source
Repositioning of vemurafenib and palbociclib as spleen tyrosine kinase inhibitors for the treatment of neuroinflammation in Ataxia–Telangiectasia. ABSTRACT Ataxia–Telangiectasia (AT) is a rare neurodegenerative disorder characterized by progressive neuronal loss and chronic neuroinflammation.
Alessia Romano +3 more
wiley +1 more source
Abstract Roux‐en‐Y gastric bypass (RYGB) is an effective surgical intervention for severe obesity, but the role of gastrointestinal hormones in its benefits remains unclear. We examined longitudinal pre‐to‐post‐meal gastrointestinal hormone changes and their relationships with glucose homeostasis and feeding‐related cognitive responses in women ...
María F. Andreoli +8 more
wiley +1 more source
Tolcapone Interferes With Key Pathological Features in Alzheimer’s Disease
Tolcapone, a clinically approved drug for the treatment of Parkinson’s disease as an adjunct therapy, has recently emerged as a potential modulator of amyloid‐β aggregation and toxicity, which are hallmark features of Alzheimer’s disease and are also involved in ocular neurodegenerative disorders, including glaucoma and age‐related macular degeneration.
Alessia Distefano +6 more
wiley +1 more source
Recent advancements in surface plasmon resonance protocols and simulations have enhanced the measurement and prediction of diffusion coefficients (D) for chemical species in microfluidic channels. These developments enable precise determination of D values for molecules ranging from a few angstroms to nanometric aggregates, facilitating detailed ...
Giuseppe Stefano Basile +4 more
wiley +1 more source
Amyloid‐β (Aβ) oligomers affect VDAC1 electrophysiology and the physiological metabolic cross‐talk between cytosol and mitochondria. The use of a small, synthetic VDAC1‐antagonist peptide, derived from hexokinase, restores mitochondrial functionality, and respiration in cellular models of Alzheimer's disease. ABSTRACT Mitochondrial dysfunction has been
Fabrizio Cavallaro +10 more
wiley +1 more source
Abstract Objective This study aimed to identify prescribing behaviors in women of childbearing potential (WOCP) with epilepsy already taking valproate (VPA), and to investigate the relationship between VPA maintenance, substitution, reduction, or withdrawal as part of polytherapy, and seizure worsening or relapse.
Roberta Esposto +16 more
wiley +1 more source

